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Pre Diabetes Screening in Primary Care
Abstract
The purpose of this evidence based practice (EBP) project was to evaluate an
electronic medical record (EMR) based American Diabetes Association pre diabetes
screening protocol in a primary care setting. Pre diabetes is an under screened condition
that can result in a diagnosis of diabetes mellitus and the risk is 56% lower for those who
had returned to normal glucose regulation versus those who consistently had pre diabetes.
Patients with a body mass index (BMI) greater than 25 were flagged in the EMR at
intake. Providers assessed for a previous HbA1C within the last year, if a HbA1c had
been ordered an EMR reminder was placed for annual screening. If a HbA1c had not
been ordered, an order was placed for a HbA1C and an EMR reminder was placed in the
chart for annual screening. Eighty patients were flagged for screening and 21% were
screened with a HbA1C at the time of the visit which was not an improvement over
previous months screening rates. Of the patients who had labs ordered at the visit for
other reasons, 55% had an HbA1c added onto visit related blood work. Of the labs
returned, 43% of the patients were found to be pre diabetic. Utilizing the EMR to
identify patients at risk for pre diabetes allows for consistency across providers in a clinic
and for program sustainability. There was still a substantial missed opportunity to screen
for pre diabetes which results in a potential $863,100 annually in diabetes related costs.
Key Words: Pre diabetes screening, preventative medicine, primary care screening
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Introduction
Diabetes mellitus is a growing health concern in the United States, it remained the
seventh leading cause of death in the United States in 2010 (American Diabetes
Association [ADA], 2015b). Complications of diabetes mellitus include hypertension,
stroke, heart attack, blindness and kidney disease and costs $176 billion in direct medical
costs each year (ADA, 2015b). Pre diabetes is a condition where the blood glucose levels
are above normal but do not meet the criteria for a diabetes mellitus diagnosis; many of
these patients will develop diabetes mellitus in the future without proper intervention.
Reducing the impact of diabetes mellitus through early recognition and treatment of pre
diabetes will reduce to overall cost of diabetes mellitus to the healthcare system and
improve patient outcomes.
Problem Existence
Pre diabetes is an under screened condition that can lead to a diagnosis of diabetes
mellitus if left unaddressed. Of those with pre diabetes, 15-30% of people diagnosed
with pre diabetes will develop type 2 diabetes mellitus within five years (Centers for
Disease Control and Prevention [CDC], 2014a). Nationally 86 million adults have pre
diabetes with almost 78 million of those undiagnosed (Centers for Disease Control and
Prevention [CDC], 2014b). Nine out of ten of those with pre diabetes are unaware of
their condition which puts them at risk for developing type 2 diabetes mellitus and the
complications associated with that disease (CDC, 2014b). In those people with pre
diabetes, losing weight and being more active can cut their risk of developing type 2
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diabetes in half (CDC, 2014b). Diabetes mellitus development risk is 56% lower for
those who had returned to normal glucose regulation versus those who consistently had
pre diabetes (Perreault et al., 2012). Identifying those with pre diabetes is an essential
step towards preventing the development of diabetes mellitus and the complications
associated with the disease.
Screening for pre diabetes is an underutilized resource in primary care, Medicare
offers free screening services but these are only used about 11.7% of the time
(NovoNorodisk, 2010). While there is no data reflecting the screening practices for pre
diabetes, an analysis by the CDC found less than 5% of patients were receiving diabetes
care according to the American Diabetes Association guidelines (National Committee for
Quality Assurance [NCQA], 2006).
The five criteria that define optimal conditions for screening for any disorder are
as follows: the disorder is an important public problem, an early asymptomatic stage
exists, there is a suitable screening test, an accepted treatment is available and early
treatment in the asymptomatic stage improves long term outcomes (McCulloch &
Hayward, 2014). As stated previously, diabetes mellitus is a substantial public problem
that is only increasing over time which addresses the first of the five criteria. Pre
diabetes is the asymptomatic stage of diabetes mellitus and there are several screening
tests that exist including glycated hemoglobin A1C, fasting blood glucose or a two hour
post glucose challenge and while there is debated about the optimal screening test all
three can detect pre diabetes which addresses the second and third criteria (McCulloch &
Hayward, 2014). The concordance between the fasting blood glucose and OGTT tests is
imperfect, as is the concordance between A1C and either glucose-based test (ADA,
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2015a). The National Health and Nutrition Examination Survey (NHANES) data
indicates that an A1C cut point of 6.5% identifies one-third fewer cases of undiagnosed
diabetes than a fasting glucose cut point of 126 mg/dL (ADA, 2015a). The ADA
recommends using the HbA1C as the test of choice for screening despite the lower
sensitivity of A1C at the designated cut point due to the test’s ease of use and facilitation
of more widespread testing (ADA, 2015a). While there is limited evidence to the long
term benefits of pre diabetes treatment, there are well established evidence to the
reduction in kidney, cardiac, ophthalmic and microvascular damage with the reduction in
blood glucose of patients with diabetes (McCulloch & Hayward, 2014). As discussed
previously, the well-established treatment for pre diabetes through diet and exercise can
reduce the progression of the disease into diabetes by almost 60% with a return to normal
blood glucose levels which addresses the fourth criteria (Perreault et al., 2012). Based on
the criteria listed above, screening for pre diabetes meets most of the five criteria except
for the direct evidence that intervention in the pre diabetes stage prevents complications
however, there is substantial evidence that glycemic control prevents complications in
diabetes mellitus and it can be reasonably assumed the results can be generalized to pre
diabetes.
Setting
The clinic setting for this EBP was a private practice located in Southern
California providing primary care services across the life span at two separate locations.
The project was implemented at one site and staff was trained via two separate sessions
as well as a power point presentation emailed to staff prior to the start date. There were
four providers in the clinic, two physicians, one physician assistant and one nurse
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practitioner. In 2015, 879 patients qualified for screening and 593 were screened which
left 70% of patients unscreened for pre diabetes.
Project Plan Process
The evidence-based program screened patients according to the 2015 American
Diabetes Association protocol which states that asymptomatic adults with a BMI greater
than 25 and one of the following risk factors should be screened; physical inactivity, first
degree relative with diabetes, high risk race (African American, Latino, Native American,
Asian American or Pacific Islander), women who delivered a baby weighing > 9lbs or
diagnosed with gestational diabetes, hypertension (blood pressure greater than or equal to
140/90) HDL cholesterol less than 35 mg/dL or triglyceride greater than 250 mg/dL,
women with polycystic ovarian disease, hgA1C greater than 5.7%, other clinical
diagnosis associated with insulin resistance, a history of CVD, or routine screening
starting at 45 years old (ADA, 2015a). Patients with a body mass index (BMI) greater
than 25 were flagged in the EMR at intake by the medical assistant (MA) who initiated a
screening questionnaire in the provider note to assess for pre diabetes with a reminder the
patient qualified for screening. Providers looked in the lab results for a previous HbA1C
within the last year: if a HbA1C had been ordered, a reminder was placed for annual
screening and if a HbA1C was not present, a lab or point of care test was ordered and a
reminder to screen was placed in the chart.
There is literature to support screening for pre diabetes based on BMI and based
on waist circumference. Clinical evidence has shown a greater association with the risk
of diabetes with central obesity and there is research that shows waist circumference has
a greater predictability for central obesity (Vazquez, Duval, Jacobs, & Silventoinen,
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2007). A meta-analysis of 32 studies showed a pooled relative risk ratios of 1.87 for the
incidence of diabetes for BMI as well as waist circumference which shows both these
methods have similar predictive ability for diabetes (Vazquez et al., 2007). Another
study reviewed 17 prospective and 35 cross sectional studies and found both BMI and
waist circumference measurement had an association for predicting diabetes and there
was not enough research on waist circumference measurement to say it is a better
predictor than BMI based on key methodological issues that affected the ability to draw
clear conclusions (Qiao & Nyamdorj, 2010). There is a high sensitivity for the waist
circumference that may be preferred to increase awareness of the disease in the public,
there is not a high specificity in diagnostic criteria which is necessary for clinical practice
(World Health Organization [WHO], 2008). Currently, most national organizations base
their diabetes screening protocols on BMI and have not included the waist circumference
measurement in the protocol (American Diabetes Association [ADA], 2015a). The
evidence as well as national screening protocols support screening based on BMI over
screening based on waist circumference measurement.
The United States Preventative Task Force (USPTF) recommends screening for
pre diabetes and is currently changing their screening recommendation from patients with
an elevated blood pressure (greater than 135/80 mmHg) to any patients who are at risk
for developing diabetes (US Preventative Services Task Force [USPSTF], 2008). There
is strong evidence from multiple long term studies that intervention during the prediabetes stage can lead to a significant reduction, 36% to 58%, in diabetes incidence in
over 3-5 years (NCQA, 2006). There are limitations to the current body of literature
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since there are no prospective studies that directly investigate the reduction in
complications of diabetes due to early intervention in the pre diabetes stage.
Project Outcomes
Over a 4-week intervention period, 80 patients qualified for pre diabetes
screening. The population focused on during this EBP were adult patients with BMI
greater than 25 without diabetes mellitus ICD-10 codes on the problem list or current
diabetic medications (insulin or metformin), non-OB or pregnancy related visits, with no
HbA1c ordered within one year. Of the 80 patients who fit screening criteria: 80 charts
were flagged for screening by the MA, 17 patients had a HbA1C ordered, 22 chart alerts
were created (Table 1). Of the 31 patients who had blood work ordered at the time of the
visit, 17 had a HbA1C added to visit related blood work. An MA driven process was
100% successful in flagging patients who qualified for screening. Of the flagged
patients, 21% were screened with a HbA1C at the time of the visit which was not an
improvement over previous months screening rates. Of the patients who had labs ordered
at the visit for other reasons, 55% had an HbA1c added onto visit related blood work.
There were substantial missed opportunities (63 patients) to screen for pre diabetes in the
at risk population. Eight weeks post intervention, of the 7 lab results that were returned 3
were found to be pre diabetic (HbA1c 5.6-6.3) and 4 were with in normal range.
There were substantial missed opportunities for screening patients, follow through
with lab results and reminders for future screening. During the 4-week intervention
period, 78% of patients that qualified for HbA1c screening were missed and at two
months post intervention, just 7 of the 17 (41%) HbA1c labs ordered were available for
review in the chart. 27% of the charts had alerts created for annual screening and more
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chart alerts were created than HbA1c ordered. Overall, the screening rates did not
increase substantially when compared to the previous 6 months screening rates (Table 2),
however when screening rates were narrowed to those who obtained blood work at the
visit the screening rates increased to 53%.
There were several areas that were very successful in identifying patients who
qualify for screening. An MA driven screening program was successful in flagging the
patients who meet the criteria, 100% of patients who needed screening had their chart
flagged by the MA at intake. Of the seven HbA1c results that were obtained, 43% of the
patients fell into the pre diabetic range and were asymptomatic at the time of screening.
Implications for Practice
Cost to the clinic to implement this screening was minimal since the protocol was
worked into the existing EMR without paying for upgrades to the existing system. The
program was built into the EMR system through alerts created by the provider which
allows sustainability and consistent screening across providers in the clinic. Flexibility of
the system for changes should be considered when purchasing an EMR system for private
practice, there were many work arounds that occurred to avoid out of pocket costs to the
clinic for system upgrades that resulted in additional steps to the screening protocol.
Ideally, diagnosis linked labs and screening reminders would streamline the screening
process but was not an available function on the EMR. Diagnosis linked labs would
remove the provider generated orders and result in a “standing” HbA1C created annually
that would allow for captured screening when labs whether are ordered for annual exams
or an episodic visit.
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Follow through on lab results is necessary to accurately screen patients, of the 17
HbA1c lab test ordered only 41% of patients had results at 2 months out. The primary
care office had point of care testing for HbA1c available but it was not utilized during the
intervention. The use of POC testing could increase the number of patients screened and
allow for immediate discussion of results as well as referrals for education. The use of
POC testing for screening could also increase revenue for the clinic at $23 per test the
clinic missed $1840 in revenue during the 4-week period of the intervention.
The annual cost of diabetes to the individual patient is $13,700 (ADA, 2015a).
The cost of missing 63 pre diabetic patients would result in a potential $863,100 annually
in diabetes related costs. Through screening for pre diabetes and patient education on
lifestyle changes a real impact can be made on reduction of diabetes mellitus rates as well
as the cost of diabetes to the healthcare system.
Conclusions
The evidence for pre diabetes screening is well documented in the literature and is
recommended by the American Diabetes association however can be difficult to
consistently implement in the primary care setting. The use of the EMR to facilitate
screening can provide consistency across providers and increase screening rates in the
clinic. Consideration for screening programs should be included in the selection of an
EMR system prior to purchase and should include the ability to link diagnosis with lab or
screening reminders. The use of a POC HbA1c testing if available to the clinic should
also be considered when screening for pre diabetes, it allows for immediate feedback and
education resources.
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Table 1
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